Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
ASCO 2024: Lung cancer roundup
Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma
ASCO 2024: Highlights and analysis
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC
Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer
Osimertinib success in locally advanced EGFR-mutated NSCLC
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
Adagrasib improves on docetaxel in previously treated NSCLC
Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis
Addition of cabazitaxel to abiraterone/prednisone significantly prolonged PFS in extensive mCRPC following docetaxel